



**Raptor Pharmaceutical Corp.**

**NASDAQ: RPTP**

**www.raptorpharma.com**

Raptor Pharmaceutical Corp. (Raptor) is focused on improving drug targeting to expand the reach and benefit of existing therapeutics into underserved patient populations. Starting with existing compounds helps us to speed the delivery of new therapies to patients. In less than four years and \$25 million, Raptor has built a NASDAQ-listed biopharmaceutical company with a product pipeline that may advance therapeutic options for ten different indications and includes the potential for both product launch and partnering revenues within the next two years.

**Recent news**

**02/10/10:** Raptor Pharmaceutical Corp. to Present Cystinosis Research at Lysosomal Disease Network’s 2010 WORLD Symposium

**01/11/10:** Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis

**12/23/09:** Raptor Pharmaceutical Corp. Announces Closing of \$7.5 Million Registered Direct Offering

**Development programs**

Our clinical-stage product pipeline includes three active development programs, and three product candidates for which we are seeking partners. Additionally, our preclinical pipeline includes one product candidate and three development programs based upon our proprietary drug-targeting platforms, one of which is currently partnered with Roche.


**Clinical development programs**

Raptor is involved in the clinical development of DR Cysteamine for the potential treatment of genetic diseases, such as nephropathic cystinosis and Huntington’s Disease, as well as metabolic diseases, such as NASH. The three product candidates for which we are actively seeking partners are Convivia™ for the management of aldehyde dehydrogenase (ALDH2) deficiency, Tezampanel for acute migraines, and NGX426 for chronic pain.

**Preclinical programs**

Raptor is bioengineering novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein (RAP) and related proteins designed to target cancer, neurodegenerative disorders and infectious diseases. Raptor’s preclinical programs include HepTide™, NeuroTrans™, WntTide™ and Tezampanel.

**Investigational Product Pipeline (Potential Clinical Indications)**





## Collaborations

Raptor partners with leading research institutions and nonprofit organizations in an effort to expand the reach and benefit of established therapeutics.

### Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY)

- Evaluating therapeutic delivery of select Roche molecules attached to NeuroTrans™ blood-brain barrier transporter platform

### University of California, San Diego (UCSD) Medical Center

- Clinical studies for DR Cysteamine in Cystinosis and NASH

### Johns Hopkins University

- License agreement for intellectual property related to the use of Tezampanel and NGX426 for thrombotic disorder

### Centre Hospitalier Universitaire d'Angers (CHU d'Angers)

- Phase 2 study of DR Cysteamine in Huntington's Disease

### Washington University, St. Louis

- Mesd technology used in our WntTide™ program for oncology applications

### Brigham and Women's Hospital

- Collaborative research agreement involving characterization of certain modified RAP proteins

### The Cystinosis Foundation

### The Cystinosis Research Foundation (CRF) (Natalie's Wish)

## Senior management

### Christopher M. Starr, Ph.D.

Chief Executive Officer, Director & Co-founder

- BioMarin Pharmaceutical Inc. (NASDAQ/SWX: BMRN) co-founder (1996-2005)
- Glyko Biomedical Ltd. (TSX: GBL) Scientific co-founder (1991-1996)
- National Institutes of Health (NIH) National Research Associate Fellow (1987-1991)

### Ted Daley

President

- Founder and CEO, Convivia, Inc.

### Patrice P. Rioux, M.D., Ph.D.

Chief Medical Officer

- CMO, FerroKin Biosciences
- CMO and VP Clinical/Regulatory, Edison Pharmaceuticals

### Todd C. Zankel, Ph.D.

Chief Scientific Officer & Co-founder

- Sr. Director of Research, BioMarin (1997-2005)

### Kim R. Tsuchimoto

Chief Financial Officer, Secretary & Treasurer

- VP Treasurer and VP Controller, BioMarin (1997-2005)

## Market profile (02/12/10)

**Ticker:** NASDAQ: RPTP

**Market capitalization:** \$49.7M

**Closing price:** \$2.20

**Avg. volume (3m):** 74,000

**52-week range:**

**Shares outstanding:** 22.6M

52-week high: \$4.90

52-week low: \$1.16

## Contacts

### Raptor Pharmaceutical Corp.

Kim R. Tsuchimoto

Chief Financial Officer

415-382-1390

ktsuchimoto@raptorpharma.com

Karl Cahill

Investor Relations

858-404-0609

kcahill@raptorpharma.com

### The Ruth Group

(investors / media)

Sara Pellegrino / Janine McCargo

646-536-7002 / 7033

spelleggrino@theruthgroup.com

jmccargo@theruthgroup.com

### Raptor Pharmaceutical Corp.

9 Commercial Blvd., Suite 200

Novato, CA 94949

415-382-8111

www.raptorpharma.com

*This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the Company's ability to develop, obtain regulatory approval and commercialize its clinical and preclinical product candidate programs. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent our forward looking statements from coming to fruition include: that we may be unsuccessful in developing any products or acquiring products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able to raise sufficient funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission (the "SEC"), which we strongly urge you to read and consider, including the joint proxy statement/prospectus on Form S-4 filed with the SEC on August 19, 2009; our annual report on Form 8-K filed with the SEC on February 5, 2010; and our quarterly report on Form 10-Q/A filed with the SEC on January 15, 2010, all of which are available free of charge on the SEC's web site at <http://www.sec.gov>. Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in our reports filed with the SEC. We expressly disclaim any intent or obligation to update any forward-looking statements.*